Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib versus placebo in systemic sclerosis-associated interstitial lung disease
MOH_2017-06-21_000545Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and systemic sclerosis (SSc) comparing Ofev twice daily with Control: placebo (2 arms). Primary endpoint: Forced vital capacity assessment at week 52. Started Feb 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on MOH_2017-06-21_000545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-21_000545.